Entero Healthcare Solutions reported a consolidated net profit of ₹520.51 million for the quarter ended June 30, 2026, marking an 89% year-on-year increase from ₹302.32 million in the corresponding period of FY26. The Mumbai-based pharmaceutical distributor saw consolidated revenue from operations rise 38% to ₹19,404.95 million, driven primarily by the inclusion of new subsidiaries acquired during FY26. This top-line expansion significantly boosted group earnings, although standalone performance diverged sharply with net profit halving to ₹34.57 million as higher finance costs offset modest revenue growth at the holding level.

The Board of Directors approved the unaudited financial results on August 7, 2026, pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Statutory auditors M S K A & Associates LLP issued limited review reports with unmodified opinions for both standalone and consolidated statements. In compliance with Regulation 47 of the SEBI (LODR) Regulations, 2015, the company published extracts of the results in 'Financial Express' and 'Satyajay Times' on August 8, 2026. The trading window for securities opened after the expiry of 48 hours from the disclosure of results.

Financial Performance

Consolidated earnings per share (EPS) rose to ₹8.77 from ₹6.39 in Q1FY26. Profit attributable to owners of the company increased 37% to ₹381.62 million. Standalone EPS fell to ₹0.79 from ₹1.60, reflecting a decline in standalone profit before tax to ₹46.05 million from ₹91.64 million. On the operational front, consolidated EBITDA nearly doubled to ₹969 million from ₹502 million year-on-year, with EBITDA margin expanding to 4.99% from 3.52%, reflecting improved operating leverage across the group's expanded subsidiary base.

The following table summarises the key financial metrics for the quarter:

Corporate Actions and Committee Reconstitution

The Board reconstituted its Audit, Nomination and Remuneration, and Stakeholders Relationship Committees effective August 25, 2026, following the completion of Rajesh Shashikant Dalal's tenure as Non-Executive Independent Director. Sandhya Gadkari Sharma chairs both the Audit and Nomination committees. Sujesh Vasudevan now chairs the Stakeholders Relationship Committee.

During the quarter, the holding company subscribed to Optionally Convertible Debentures (OCDs) issued by four subsidiaries: Saurashtra Medisolutions Private Limited, Sri Parshva Pharma Distributors Private Limited, S.S. Pharma Traders Private Limited, and Avenues Pharma Distributors Private Limited. The company also allotted 12,135 equity shares at a premium of ₹794 per share, aggregating to ₹9.76 million, pursuant to employee stock option exercises. Additionally, 24,800 ESOPs were granted under the Entero Employee Stock Option Plan 2023.

What the Numbers Show

A significant divergence exists between consolidated and standalone profitability drivers. While consolidated revenue surged 38% YoY, standalone revenue grew only 5%. More critically, standalone other income dropped 12% to ₹231.45 million from ₹262.88 million, and finance costs nearly decapentupled to ₹57.42 million from ₹5.94 million. This suggests that the holding company is bearing disproportionate financing costs relative to its operational scale, whereas subsidiaries are generating the bulk of the group's operational leverage. The consolidation of seven new entities during FY26—such as Ramson Medical Distributors and Anand Chemiceutics—explains the top-line expansion but also introduces integration complexity, evidenced by the non-comparability of certain quarterly figures.

Entero Healthcare Solutions has issued a revised intimation for its upcoming earnings call scheduled for August 10, 2026. The company, which manufactures medical devices and healthcare products, will discuss its unaudited financial results for the quarter ended June 30, 2026 (Q1FY27). The revision, filed with stock exchanges on August 5, 2026, pertains solely to the meeting link, with no changes to the time or other logistical details previously communicated.

The updated notice was submitted pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015. Sanu Kapoor, Vice President- Group General Counsel, Company Secretary & Compliance Officer, signed the revised letter bearing reference number 29/SE/LC/2026-27. This filing supersedes the earlier intimation dated August 4, 2026, which had announced the initial schedule for the conference call.

Management Participation

The earnings call will feature key executives from Entero Healthcare Solutions who provide strategic oversight and financial guidance for the organization. Investors and analysts will have the opportunity to engage directly with leadership regarding Q1FY27 performance metrics and operational updates.

These leaders will address queries regarding the company's quarterly performance, market positioning, and strategic initiatives undertaken during the period. Their presence ensures that stakeholders receive direct insights into both operational execution and financial stewardship.

Event Logistics

Monarch Networth Capital serves as the organizer for the conference call, facilitating access for domestic and international participants. The event offers multiple dial-in options to ensure broad accessibility for stakeholders across different geographies. Participants can also join via an Express Join link using a Diamond Pass, the details of which were corrected in this revised notice.

For RSVPs and further assistance, Mr. Rahul Dani at Monarch Networth Capital remains the designated point of contact. The company noted that while the meeting link has been updated, changes to the schedule or format may still occur due to exigencies on the part of the host or the company.